Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy

por Wang, Yuqing, Du, Jiang, Gao, Zhenyue, Sun, Haoyang, Mei, Mei, Wang, Yu, Ren, Yu, Zhou, Xuan
Publicado 2022

Pharmacokinetics and bioequivalence of sunitinib and Sutent(®) in Chinese healthy subjects: an open-label, randomized, crossover study

por Wang, Yanli, Deng, Qiaohuan, Gao, Zhenyue, Liu, Guangwen, Su, Zhengjie, Zhao, Yicheng, Zhang, Lixiu, Yang, Haimiao
Publicado 2023

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy

por Xu, Yiqi, Gao, Zhenyue, Hu, Ruxin, Wang, Yuqing, Wang, Yuhong, Su, Zheng, Zhang, Xiaoyue, Yang, Jingxuan, Mei, Mei, Ren, Yu, Li, Min, Zhou, Xuan
Publicado 2021

PD-L2 based immune signature confers poor prognosis in HNSCC

por Qiao, Yu, Liu, Chao, Zhang, Xiaoyue, Zhou, Qianqian, Li, Yatian, Xu, Yini, Gao, Zhenyue, Xu, Yiqi, Kong, Lingping, Yang, Aifeng, Mei, Mei, Ren, Yu, Wang, Xudong, Zhou, Xuan
Publicado 2021

Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma

por Li, Yatian, Gao, Zhenyue, Wang, Yuhong, Pang, Bo, Zhang, Binbin, Hu, Ruxin, Wang, Yuqing, Liu, Chao, Zhang, Xuebin, Yang, Jingxuan, Mei, Mei, Wang, Yongzhi, Zhou, Xuan, Li, Min, Ren, Yu
Publicado 2023